About the Nonalcoholic Fatty Liver
Disease (NAFLD) Fibrosis Score Panel
What is it?
This panel identifies patients with nonalcoholic fatty liver disease (NAFLD) who are at highest risk of progressing to serious liver disease. It also identifies patients at low risk of progression who should continue to be assessed and monitored for NAFLD. Patients with a high score may need to be referred for further liver function assessment. The fibrosis score, which is based on test values and patient clinical information, is calculated free of charge.
While overall prevalence of NAFLD is estimated to be anywhere from 6.3% to 33%, the rate is more than double that in people with type 2 diabetes.1 In recent studies, NAFLD has been shown to predict the development of type 2 diabetes, and vice versa.2 Each condition may serve as a progression factor for the other, and some complications of diabetes may be directly linked to NAFLD.2
The panel assesses the following:
- Serum glucose
- Platelet count
- AST/ALT ratio
- Patient characteristics such as age, BMI, and diabetes status
NAFLD, NASH, and the diabetes connection
NAFLD is a liver condition that is associated with obesity, diabetes, and dyslipidemia. In its most indolent form (simple steatosis), NAFLD is characterized by the histologic accumulation of fat within hepatocytes. In some patients, this fat accumulation is accompanied by varying degrees of inflammation and fibrosis—nonalcoholic steatohepatitis (NASH)—which may progress to cirrhosis and attendant complications.
When should you use it?
When bridging fibrosis and/or cirrhosis is suspected.
What makes it different?
The NAFLD Fibrosis Score Panel is a validated, noninvasive tool for identifying patients whose NAFLD has advanced to liver fibrosis. It relies on readily available clinical information and routinely measured laboratory data. The NAFLD Fibrosis Score is recommended by the American Association for the Study of Liver Diseases (AASLD), the American College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA). All three organizations consider it a clinically useful tool for identifying patients at high risk for bridging fibrosis and/or cirrhosis.1
Let us help you know what’s ahead
Contact a Quest Diagnostics sales representative to learn more
Want to learn more about NAFLD testing?
1 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:
practice guideline by the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American Gastroenterological Association.
2 Williams KH, Shackel NA, Gorrell MD, et al. Diabetes and nonalcoholic fatty liver disease:
a pathogenic duo. Endocr Rev. 2013;34:84-129.